Skip to main content
. 2018 Jan 18;23(1):201. doi: 10.3390/molecules23010201

Figure 4.

Figure 4

TrLp is significantly more potent than CLp in causing suppression of CD133(+) and SOX2(+) GL261 stem cells. Treated GL261 cells were stained with antibodies against CD133 and SOX2 and analyzed via flow cytometry. (A,E,F) The Vehicle-treated GL261 cells showed an abundance of CD133(+) GBM stem cells (UL quadrant, within the red rectangle). (A–C,E,F) Compared to the Vehicle-treated, the CLp-treated cells (UL quadrant, within the red rectangle) showed a 69% suppression of CD133 IF (* p = 1.2 × 10−3) and TrLp-treated cells (UL quadrant, within the red rectangle) showed a 92% suppression of CD133(+) IF (** p = 6.9 × 10−4) (E,F); (F) TrLp treatment yielded 23% greater suppression of CD133 IF than CLp (Δ p = 1.6 × 10−3); (D) 2° antibody staining showed background fluorescence; (G–I,K,L) Compared to the Vehicle-treated cells, the CLp-treated cells (UL quadrant, within the red circle) showed 56% suppression of SOX2 IF (* p = 3.2 × 10−3), and the TrLp-treated cells showed 82% suppression of SOX2 IF (** p = 1.0 × 10−3) (K,L); (L) This inhibition was 26% greater in the TrLp group than in the CLp group (Δ p = 5.6 × 10−3). Data (mean ± S.E.M.) were obtained from Vehicle (n = 3), CLp (n = 3) and TrLp (n = 3); (J) 2° antibody-treated samples showed background staining.